Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 7, 2016, Pages 1022-1030.e4

  Pisani, Antonio ^a   Sabbatini, Massimo ^a   Imbriaco, Massimo ^a   Riccio, Eleonora ^a   Rubis, Nadia ^b   Prinster, Anna ^c   Perna, Annalisa ^b   Liuzzi, Raffaele ^c   Spinelli, Letizia ^a   Santangelo, Michele ^a   Remuzzi, Giuseppe ^b,d,e   Ruggenenti, Piero ^b,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c CNR   (Italy)

^d Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

ADPKD volume; Cyst growth; Somatostatin analogue

Indexed keywords

LONG ACTING DRUG; OCTREOTIDE; PLACEBO; GASTROINTESTINAL AGENT;

ACUTE CHOLECYSTITIS; ADULT; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; ITALY; KIDNEY POLYCYSTIC DISEASE; LIVER POLYCYSTIC DISEASE; LIVER PROTECTION; LIVER WEIGHT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; COMPLICATION; CYSTS; DIAGNOSTIC IMAGING; DRUG EFFECTS; LIVER; LIVER DISEASES; PATHOLOGY; SINGLE BLIND PROCEDURE; TIME; TREATMENT OUTCOME;

ADULT; CYSTS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; ITALY; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MALE; OCTREOTIDE; PLACEBOS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME; TREATMENT OUTCOME;

EID: 84973641543     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.12.049     Document Type: Article

References (29)

1. Van Keimpema L., De Koning D.B., Van Hoek B., et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011, 31:92-98.
2. Reynolds D.M., Falk C.T., Li A., et al. Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Am J Hum Genet 2000, 67:1598-1604.
3. Bae K.T., Zhu F., Chapman A.B., et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006, 1:64-69.
4. Wijnands T.F., Neijenhuis M.K., Kievit W., et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int 2014, 34:1578-1583.
5. Torres V.E., Rastogi S., King B.F., et al. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994, 5:1186-1192.
6. Torres V.E., Harris P.C., Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007, 369:1287-1301.
7. Ruggenenti P., Remuzzi A., Ondei P., et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005, 68:206-216.
8. Lamberts S.W., van der Lely A.J., de Herder W.W., et al. Octreotide. N Engl J Med 1996, 334:246-254.
9. Belibi F.A., Reif G., Wallace D.P., et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004, 66:964-973.
10. Silva P., Stoff J.S., Leone D.R., et al. Mode of action of somatostatin to inhibit secretion by shark rectal gland. Am J Physiol 1985, 249:R329-R334.
11. Caroli A., Antiga L., Cafaro M., et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010, 5:783-789.
12. Masyuk T.V., Masyuk A.I., Torres V.E., et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007, 132:1104-1116.
13. Caroli A., Perico N., Perna A., et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013, 382:1485-1495.
14. Gigot J.F., Jadoul P., Que F., et al. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management?. Ann Surg 1997, 225:286-294.
15. Melmed S., Dowling R.H., Frohman L., et al. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 1994, 97:468-473.
16. van Keimpema L., Nevens F., Vanslembrouck R., et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009, 137. 1661-1668 e1-e2.
17. Hogan M.C., Masyuk T.V., Page L.J., et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010, 21:1052-1061.
18. Gevers T.J., Inthout J., Caroli A., et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology 2013, 145. 357-365 e1-e2.
19. Chrispijn M., Nevens F., Gevers T.J., et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012, 35:266-274.
20. Torres V.E., Chapman A.B., Devuyst O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012, 367:2407-2418.
21. Shillingford J.M., Murcia N.S., Larson C.H., et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006, 103:5466-5471.
22. Qian Q., Du H., King B.F., et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008, 19:631-638.
23. Walz G., Budde K., Mannaa M., et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010, 363:830-840.
24. Serra A.L., Poster D., Kistler A.D., et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010, 363:820-829.
25. Chrispijn M., Gevers T.J., Hol J.C., et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol 2013, 59:153-159.
26. Giustina A., Mazziotti G., Torri V., et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 2012, 7:e36411.
27. Chapman A.B., Guay-Woodford L.M., Grantham J.J., et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003, 64:1035-1045.
28. Caroli A., Perico N., Perna A., et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013, 382:1485-1495.
29. Caroli A., Antiga L., Cafaro M., et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010, 5:783.